10-K: NorthView Acquisition Corp. Files 10-K, Details Merger Agreement and Financials

NorthView Acquisition Corp.'s annual report on Form 10-K details the company's financials, merger agreement with Profusa, and ongoing efforts to complete a business combination.

Summary

• NorthView Acquisition Corp., a blank check company, filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The company is focused on completing a business combination, particularly targeting healthcare innovation companies.
• A merger agreement with Profusa, Inc. was entered into on November 7, 2022, with a pre-transaction equity value of $155 million for Profusa.
• The merger includes potential earnout shares for Profusa stockholders based on stock price and revenue milestones.
• The company extended its business combination period to March 22, 2024, after two shareholder votes.
• As of December 31, 2023, NorthView had approximately $9.3 million in its trust account.
• The company received a Nasdaq delisting notification for not holding an annual meeting within twelve months of its fiscal year end, and is working to regain compliance.
• NorthView reported a net income of $1,161,910 for the year ended December 31, 2023, primarily due to interest income and changes in the fair value of warrant liabilities.
• The company has a working capital deficit of $3,345,130 as of December 31, 2023, and has incurred significant costs related to the proposed merger.
• The company has a convertible promissory note with its sponsor for $1,121,815, which is presented at a fair value of $944,118 as of December 31, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress with the merger agreement and some positive financial results, the delisting notice, working capital deficit, and time constraints create significant uncertainty and risk. The sentiment is cautiously negative.

Positives

• The company has a merger agreement in place with Profusa, Inc., indicating progress towards a business combination.
• The company has a significant amount of cash in its trust account, approximately $9.3 million, to fund a business combination.
• The company reported a net income of $1,161,910 for the year ended December 31, 2023, indicating some financial success.
• The company has secured a convertible promissory note with its sponsor, providing additional financial flexibility.

Negatives

• The company has a working capital deficit of $3,345,130 as of December 31, 2023, indicating potential financial challenges.
• The company received a Nasdaq delisting notification for not holding an annual meeting, raising concerns about compliance.
• The company has incurred significant costs related to the proposed merger, which may impact its financial position.
• The company has a limited time to complete the business combination, which may put pressure on negotiations.

Risks

• The company may not be able to complete the business combination with Profusa, incurring substantial costs.
• The company may not be able to find additional sources of financing to cover costs if the merger fails.
• The company faces competition for attractive target businesses, which could increase costs or prevent a deal.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to complete a business combination.
• The company may issue shares at a price less than the prevailing market price, diluting existing shareholders.
• The company's executive officers and directors have other business commitments, potentially causing conflicts of interest.
• The company may be solely dependent on a single business after the combination, lacking diversification.
• The company may not be able to complete the business combination within the prescribed time frame, leading to liquidation.
• The company may not be able to assess the management of a target business adequately.
• The company may engage in a business combination with a target that has relationships with affiliated entities, raising potential conflicts of interest.
• The company may be unable to obtain additional financing to complete the business combination or fund the operations of a target business.
• The company's search for a business combination may be materially adversely affected by the COVID-19 pandemic.
• The company may be required to take write-downs or write-offs after the business combination, negatively impacting its financial condition.
• The company may be subject to a second level of U.S. federal income tax if it is determined to be a personal holding company.
• Non-U.S. Holders may be subject to U.S. federal income tax if the company is considered a United States real property holding corporation.

Future Outlook

The company is focused on completing its business combination with Profusa, Inc. by March 22, 2024, and is working to regain compliance with Nasdaq listing rules. The company's future success depends on the performance of the combined entity after the merger.

Management Comments

• Management believes that the combination of a high-quality management team with extensive operational, financial, merger and acquisition, and public company experience, combined with the resources of a high quality investment bank focused on evaluating and assisting quality private companies to access the public markets, is an attractive format.
• Management intends to devote as much of their time as they deem necessary to the company's affairs until the initial business combination is completed.

Industry Context

The document highlights the challenges and opportunities faced by special purpose acquisition companies (SPACs) in the current market, including increased competition for target businesses and the need to navigate complex regulatory requirements. The focus on healthcare innovation aligns with a growing trend in the SPAC market, where companies are seeking to capitalize on the demand for new technologies and treatments.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards, but it does highlight the challenges faced by SPACs in general, such as the need to complete a business combination within a limited timeframe and the risk of redemptions by public stockholders.
• The company's financial metrics, such as its working capital deficit and net income, are not directly compared to industry benchmarks, but they provide a snapshot of the company's current financial health.
• The company's efforts to regain compliance with Nasdaq listing rules are consistent with the challenges faced by other SPACs that have failed to meet listing requirements.
• The company's focus on healthcare innovation is a common theme among SPACs, but the specific terms of the merger agreement with Profusa, Inc. are unique to this transaction.

Related Party Transactions

• The company has a convertible promissory note with its sponsor.
• The company had an administrative services agreement with its sponsor, which was terminated in June 2023.
• The company may obtain loans from its initial stockholders or an affiliate to finance transaction costs.
• The company may pay consulting, finder or success fees to its initial stockholders, officers, directors or their affiliates for assisting in consummating the initial business combination.

Stakeholder Impact

• Shareholders face the risk of dilution if additional shares are issued to complete the merger.
• Shareholders may face losses if the company fails to complete the merger and liquidates.
• Shareholders may have their shares redeemed if they vote against the merger or if the company fails to complete the merger.
• Employees of the target company may be impacted by the merger, including potential changes in management or compensation.
• Creditors of the company may have claims against the trust account if the company fails to complete the merger.

Next Steps

• The company needs to complete its business combination with Profusa, Inc. by March 22, 2024.
• The company needs to submit a plan to Nasdaq to regain compliance with listing rules.
• The company needs to secure additional financing if required to complete the merger.
• The company needs to finalize the terms of the merger agreement and obtain shareholder approval.

Key Dates

Keywords

business combination, merger, acquisition, healthcare innovation, SPAC, Profusa, financial statements, warrants, redemption, Nasdaq, delisting, trust account, earnouts, convertible note